March 16, 2023
A group of patients diagnosed with inflammatory diseases will receive almost $40 million from Johnson & Johnson after a Pennsylvania federal judge gave final approval to a settlement over accusations that the company blocked health care providers from purchasing competing drugs despite lower pricing through its "Biosimilar Readiness Plan."